NAFLD vs NASH: What's the Difference?

The distinction between NAFLD and NASH represents one of the most clinically important separations within the broad category of fatty liver disease. The terms are sometimes used interchangeably in casual conversation, but they refer to distinctly different conditions with substantially different implications for prognosis and management. NAFLD encompasses the entire spectrum of non-alcoholic fatty liver disease, from simple fat accumulation through advanced fibrosis and cirrhosis. NASH refers specifically to a subset of NAFLD patients who have inflammation and liver cell injury in addition to fat accumulation. The presence of NASH typically signals a more concerning condition with higher risk of progression than simple fatty liver alone.

The clinical importance of distinguishing the two reflects substantial differences in natural history. Patients with simple steatosis (fat accumulation without inflammation) typically have stable disease over years to decades, with relatively low risk of progression to cirrhosis. Patients with NASH face substantially higher risks. The inflammatory component damages liver cells progressively, with eventual scarring (fibrosis) developing over time. Without intervention, this scarring can advance through stages, ultimately producing cirrhosis with all its serious complications. The identification of NASH supports more intensive monitoring, more aggressive intervention, and consideration of specific therapies that may not be appropriate for simple steatosis.

The challenge in modern fatty liver disease care is that distinguishing NAFLD from NASH definitively requires liver biopsy, an invasive procedure that cannot be performed in all patients. Various non-invasive approaches have been developed to estimate the likelihood of NASH, but none replace biopsy as the gold standard for definitive diagnosis. The clinical approach therefore involves combining various assessments to estimate risk, with biopsy reserved for situations where the additional information will affect management.

The terminology has continued to evolve. Updated nomenclature proposed in 2023 uses MASLD (metabolic dysfunction-associated steatotic liver disease) for NAFLD and MASH (metabolic dysfunction-associated steatohepatitis) for NASH. The newer terms emphasize the metabolic basis of these conditions. The older NAFLD/NASH terminology remains widely used in current practice, with both terminologies appearing in clinical and research contexts.

This article explains the distinction between NAFLD and NASH, examines what differentiates them clinically and pathologically, discusses how the distinction is made and why it matters, and frames the implications for patient care. The understanding supports informed engagement with fatty liver disease care.

For more on fatty liver disease, see What Is Fatty Liver Disease (NAFLD)?.

⸻

Understanding the Spectrum

The relationship between NAFLD and NASH reflects a spectrum of disease severity within the broader category of fatty liver disease.

NAFLD as the Broader Category

NAFLD encompasses the entire spectrum of fatty liver disease not caused by significant alcohol consumption. The category includes patients with simple fat accumulation through those with cirrhosis from progression of the disease. The defining feature of NAFLD is fat accumulation in liver cells exceeding 5 percent of liver tissue. Various mechanisms contribute to this accumulation, with insulin resistance and metabolic dysfunction being central.

Simple Steatosis (NAFL)

Simple steatosis, sometimes called NAFL (non-alcoholic fatty liver), represents the simplest form. The condition involves fat accumulation without significant inflammation or liver cell injury. Most patients with NAFLD have simple steatosis. Estimates suggest 70 to 80 percent of NAFLD patients have this form rather than NASH. Simple steatosis carries relatively low risk of progression to cirrhosis. The condition is associated with cardiovascular risk through shared metabolic mechanisms but has limited liver-specific consequences in most patients.

NASH (Non-Alcoholic Steatohepatitis)

NASH represents the more aggressive form. The condition involves fat accumulation with inflammation and liver cell injury. Approximately 20 to 30 percent of NAFLD patients have NASH. The numbers may be higher in certain populations including those with type 2 diabetes. NASH carries substantially higher risk of progression to fibrosis and ultimately cirrhosis. Identification of NASH affects management and monitoring substantially.

Fibrosis Stages

Beyond the simple distinction between NAFL and NASH, the degree of fibrosis (scarring) is the strongest predictor of liver-related complications:

• Stage 1 (mild fibrosis) involves limited scarring around blood vessels.
• Stage 2 (moderate fibrosis) involves more extensive scarring.
• Stage 3 (advanced fibrosis or bridging fibrosis) involves extensive scarring connecting different areas.
• Stage 4 (cirrhosis) involves the most severe scarring with substantial structural changes.

The fibrosis stage may be more important prognostically than the simple distinction between NAFL and NASH.

For more on disease stages, see Stages of Fatty Liver Disease.

⸻

What Differentiates NASH From Simple Steatosis

Several specific findings distinguish NASH from simple steatosis on liver biopsy.

Hepatocellular Injury

Hepatocellular injury, evidenced by ballooning degeneration (swelling of liver cells), is a key feature of NASH. The injury indicates active liver cell damage rather than just fat accumulation.

Inflammation

Lobular inflammation involves inflammatory cells (typically lymphocytes and other immune cells) within the liver tissue. The inflammation reflects active disease processes.

Mallory-Denk Bodies

Mallory-Denk bodies are abnormal protein aggregates within liver cells, sometimes seen in NASH.

NAFLD Activity Score (NAS)

The NAFLD Activity Score (NAS) provides a standardized assessment combining steatosis, lobular inflammation, and ballooning degeneration. Scores of 5 or greater (on a scale of 0 to 8) typically indicate NASH.

Fibrosis Assessment

Fibrosis is assessed separately from the NAS using specific staging systems. The fibrosis stage provides important prognostic information.

⸻

Why the Distinction Matters

The distinction between NAFL and NASH affects multiple aspects of care.

Prognosis

The natural history of NAFL versus NASH differs substantially. Patients with NAFL have lower risks of liver-related complications. Patients with NASH have higher risks of progression and complications.

Management Intensity

NASH typically warrants more intensive management including more rigorous lifestyle interventions, more aggressive treatment of associated conditions, and consideration of specific therapies.

Monitoring

NASH typically warrants more intensive monitoring including more frequent reassessment of liver function and possibly fibrosis progression.

Specific Therapy Eligibility

Specific therapies that have emerged for fatty liver disease are typically appropriate for patients with NASH and significant fibrosis rather than simple NAFL. Resmetirom, the first FDA-approved medication for the condition (approved 2024), is specifically for NASH with significant fibrosis.

For more on reversibility, see Can Fatty Liver Be Reversed?.

Risk Communication

The distinction affects how risks are communicated to patients. Patients with NASH need to understand they have a higher-risk form of fatty liver disease warranting attention. Patients with NAFL can be reassured that simple steatosis typically does not progress to severe disease.

⸻

How the Distinction Is Made

Distinguishing NAFL from NASH involves several approaches.

Liver Biopsy

Liver biopsy remains the gold standard for definitive diagnosis. The technique provides direct examination of liver tissue and the most accurate assessment of inflammation, hepatocellular injury, and fibrosis. The procedure involves taking a small sample of liver tissue, typically through a needle inserted through the skin under imaging guidance. The procedure has small risks and limitations. Biopsy is reserved for situations where the information will affect management. Most patients are evaluated and managed without biopsy.

Non-Invasive Assessment

Various non-invasive approaches estimate the likelihood of NASH and significant fibrosis. While none replace biopsy as the gold standard, the approaches support clinical decision-making. Imaging including ultrasound, CT, and MRI can detect steatosis but typically cannot distinguish NAFL from NASH directly. MRI proton density fat fraction (MRI-PDFF) provides quantitative assessment of liver fat.

Fibrosis Assessment

Various approaches assess fibrosis without biopsy:

• Transient elastography (FibroScan) measures liver stiffness, which correlates with fibrosis.
• MR elastography is another technique evaluating liver stiffness.
• Acoustic radiation force impulse (ARFI) imaging is a related technique using ultrasound.

Blood-Based Tests

Various blood-based tests estimate fibrosis risk:

• The FIB-4 index combines age, AST, ALT, and platelet count to estimate fibrosis risk.
• The NAFLD Fibrosis Score combines age, BMI, presence of diabetes, AST/ALT ratio, platelet count, and albumin.
• The Enhanced Liver Fibrosis (ELF) score is a more direct biomarker panel.

Combined Approaches

Combined approaches using multiple non-invasive tests typically work better than any single test. The combinations support stratification of patients into low, intermediate, and high probability categories.

When Biopsy Is Considered

Biopsy is considered for patients with intermediate or unclear results from non-invasive testing, those being considered for specific therapies that require histological diagnosis, those participating in clinical trials, and various other specific situations.

For more on imaging, see Advanced Imaging Technologies in Medicine.

⸻

Risk Factors for Progression

Beyond the simple distinction between NAFL and NASH, various factors affect progression risk.

Diabetes

Type 2 diabetes is a strong risk factor for NASH and progression. Patients with diabetes have higher rates of NASH and faster progression than those without.

Severity of Obesity

Greater obesity, particularly visceral obesity, increases risk of NASH and progression.

Metabolic Syndrome Components

Multiple components of metabolic syndrome (hypertension, dyslipidemia, abnormal glucose metabolism) increase risk.

Age

Older age is associated with greater risk of advanced disease.

Genetic Factors

Genetic factors including specific variants in PNPLA3 and other genes affect both risk and progression.

Various Other Factors

Various other factors including ethnic background, gender, and specific medical conditions affect risk.

⸻

Treatment Implications

Treatment approaches differ somewhat based on whether patients have NAFL versus NASH.

Lifestyle Interventions

Lifestyle interventions are appropriate for all NAFLD patients regardless of whether they have NAFL or NASH. Weight loss, dietary modifications, and physical activity benefit both. For NASH patients, the goals may be more ambitious and the intensity of interventions greater.

Treatment of Associated Conditions

Treatment of associated conditions including diabetes, hypertension, and dyslipidemia benefits all NAFLD patients but may be particularly important for NASH patients.

Specific Medications

Specific medications for fatty liver disease are typically appropriate for NASH patients with significant fibrosis rather than NAFL patients:

• Resmetirom, the first FDA-approved medication, is specifically for NASH with significant fibrosis.
• GLP-1 receptor agonists have shown benefits in NASH and may be appropriate for selected patients.
• Vitamin E has been studied with some demonstrated benefit in NASH.
• Pioglitazone has been studied with some demonstrated benefit in NASH.

Bariatric Surgery

Bariatric surgery for severe obesity benefits both NAFL and NASH patients. The procedures can produce dramatic improvements in fatty liver disease.

For more on exercise, see Best Exercise for Fatty Liver Disease.

⸻

Monitoring Differences

Monitoring approaches differ between NAFL and NASH patients.

NAFL Monitoring

Patients with NAFL typically undergo less intensive monitoring. Periodic reassessment may include liver function tests and assessment of metabolic risk factors. Repeat assessment for progression to NASH or development of fibrosis may be appropriate over time.

NASH Monitoring

Patients with NASH typically undergo more intensive monitoring. The monitoring includes regular liver function assessments, fibrosis assessment using non-invasive techniques, assessment of treatment response, and various other elements. For patients with cirrhosis from NASH, additional monitoring including hepatocellular carcinoma surveillance is appropriate.

Specialist Involvement

Hepatology specialist involvement is more often appropriate for NASH patients than for those with simple NAFL.

⸻

Common Misconceptions

Several misconceptions about the NAFLD/NASH distinction deserve attention.

Misconception: NAFLD and NASH Are the Same

NAFLD and NASH are different conditions. NASH is a subset of NAFLD with more concerning features.

Misconception: All NAFLD Becomes NASH

Most patients with NAFLD do not progress to NASH. Approximately 20 to 30 percent have NASH.

Misconception: Only NASH Patients Need Treatment

All NAFLD patients benefit from lifestyle interventions and management of associated conditions. The intensity of interventions may differ.

Misconception: Liver Tests Distinguish NAFL From NASH

Liver function tests can be normal in both NAFL and NASH. The tests do not reliably distinguish the conditions.

Misconception: NASH Always Means Cirrhosis Is Coming

While NASH increases risk of progression, many NASH patients do not progress to cirrhosis. Various factors affect individual risk.

Misconception: Once You Have NASH, You Always Have NASH

NASH can improve with appropriate intervention. Weight loss and various other interventions can reduce inflammation and even improve fibrosis.

For more on broader misdiagnosis, see Most Commonly Misdiagnosed Conditions.

⸻

Special Patient Populations

Several specific populations have particular considerations regarding NAFLD versus NASH.

Patients With Diabetes

Patients with type 2 diabetes have higher rates of NASH. Aggressive management addresses both conditions.

Lean Patients

Some patients have NAFLD without significant obesity (lean NAFLD). The condition has somewhat different characteristics and progression patterns.

Older Adults

Older adults have higher prevalence of advanced disease. Comprehensive management addresses both NAFLD-specific and broader health considerations.

Pediatric Patients

NAFLD increasingly affects children and adolescents. The pediatric form has somewhat different characteristics and management considerations.

For more on alcohol-related distinction, see Alcohol vs Non-Alcoholic Fatty Liver Disease.

⸻

When to See a Specialist

Several situations warrant specialist evaluation. Hepatology referral is appropriate for patients with significant fibrosis, those who may benefit from specific therapies, and various other situations. Gastroenterologists evaluate many NAFLD patients, particularly those without significant fibrosis. Endocrinologists may be involved for patients with diabetes or other metabolic conditions. For complex situations, evaluation at major medical centers with comprehensive liver disease programs provides access to specialized expertise including clinical trials of newer therapies.

⸻

Conclusion

NAFLD and NASH are related but distinct conditions within the spectrum of fatty liver disease. NAFLD is the broader category encompassing all forms of non-alcoholic fatty liver disease, from simple steatosis through cirrhosis. NASH is a specific subset of NAFLD characterized by fat accumulation with inflammation and liver cell injury.

The distinction matters because NASH carries substantially higher risk of progression to fibrosis and cirrhosis than simple steatosis. Approximately 20 to 30 percent of NAFLD patients have NASH, with the others having simple steatosis.

Liver biopsy remains the gold standard for definitive distinction between NAFL and NASH. Various non-invasive approaches including imaging, transient elastography, MR elastography, and various blood-based tests support clinical assessment without biopsy. Combined approaches typically work better than any single test.

Risk factors for progression include diabetes, severity of obesity, metabolic syndrome components, age, genetic factors, and various others. Identification of higher-risk patients supports more intensive monitoring and intervention.

Treatment approaches for both NAFL and NASH include lifestyle interventions and management of associated conditions. Specific medications for fatty liver disease are typically appropriate for NASH with significant fibrosis. Resmetirom, the first FDA-approved medication for the condition, is specifically for NASH with significant fibrosis. Bariatric surgery benefits both conditions.

Monitoring approaches differ, with NASH patients typically receiving more intensive surveillance. Specialist involvement is more often appropriate for NASH patients.

The encouraging element of fatty liver disease care is that even NASH can substantially improve with appropriate intervention. Weight loss and various other interventions can reduce inflammation and even improve fibrosis. The combination of lifestyle modifications, treatment of associated conditions, and increasingly specific therapies produces good outcomes for many patients.

For most patients with fatty liver disease, the practical messages are clear. Understand the distinction between NAFL and NASH and what it means for your specific situation. Engage with appropriate evaluation to characterize your disease. Pursue lifestyle modifications regardless of whether you have NAFL or NASH. Consider specialist evaluation when appropriate. The combination of patient engagement with comprehensive care provides the foundation for the best possible outcomes for both forms of fatty liver disease.

⸻

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.